Lipoprotien electrophoresis has been a utilized technology in the clinical laboratory since the 1960’s. Agarose electrophoresis, with cholesterol staining, has more recently been used as a means to quantitate Lp(a) cholesterol. Lipoprotein (a) [Lp(a)] was discovered in the early 1960’s and has been associated with cardiovascular disease in many studies. This educational session will describe why Lp(a) is atherogenic and the reason for the difficulty of measurement. Results from the JUPITER trial will be reviewed. In addition, staining of electrophoretic patterns for triglycerides can now be accomplished. The triglyceride content of lipoprotein particles may actually provide more relevant clinical information than lipoprotein cholesterol measures. The method for such analysis will be described and the clinical implications discussed in this symposium.